AstraZeneca has launched a new initiative to improve its process of drug discovery and development.
Craig Venter, one of the scientists who first sequenced the human genome, is among the research partners working with the company to develop a database from samples donated by patients in its clinical trials, which will be coupled with drug response data. The goal is to develop more effective therapies for patients. Any future findings will be published in peer-reviewed journals, the company said. CF